Insider Transactions in Q1 2022 at Laboratory Corp Of America Holdings (LH)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,449
-31.66%
|
$678,373
$277.11 P/Share
|
|
Mar 29
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
2,356
-26.29%
|
$652,612
$277.11 P/Share
|
|
Mar 28
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-19.84%
|
$252,540
$276.42 P/Share
|
|
Mar 28
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,792
-18.81%
|
$494,592
$276.42 P/Share
|
|
Mar 28
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,885
-17.38%
|
$520,260
$276.42 P/Share
|
|
Mar 28
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-12.15%
|
$454,848
$276.42 P/Share
|
|
Mar 28
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
6,286
-10.76%
|
$1,734,936
$276.42 P/Share
|
|
Mar 28
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,883
-11.76%
|
$519,708
$276.42 P/Share
|
|
Mar 28
2022
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,360
-10.8%
|
$651,360
$276.42 P/Share
|
|
Mar 27
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,822
+37.97%
|
-
|
|
Mar 27
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+30.8%
|
-
|
|
Mar 27
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+28.11%
|
-
|
|
Mar 27
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Grant, award, or other acquisition
|
Direct |
3,707
+21.47%
|
-
|
|
Mar 27
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Grant, award, or other acquisition
|
Direct |
14,144
+19.49%
|
-
|
|
Mar 27
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
4,241
+20.94%
|
-
|
|
Mar 27
2022
|
Lance Berberian EVP, CIO & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
5,310
+19.54%
|
-
|
|
Mar 25
2022
|
R Sanders Williams Director |
SELL
Open market or private sale
|
Direct |
572
-8.17%
|
$155,584
$272.98 P/Share
|
|
Mar 25
2022
|
Kathryn E Wengel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
603
+50.0%
|
-
|
|
Mar 10
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
249
-49.9%
|
$65,238
$262.21 P/Share
|
|
Feb 16
2022
|
Peter M Neupert Director |
BUY
Open market or private purchase
|
Direct |
3,500
+11.21%
|
$920,500
$263.8 P/Share
|
|
Feb 15
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
207
-3.77%
|
$56,511
$273.98 P/Share
|
|
Feb 15
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
207
-3.04%
|
$56,511
$273.98 P/Share
|
|
Feb 14
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.38%
|
$20,944
$272.68 P/Share
|
|
Feb 14
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-1.12%
|
$20,944
$272.68 P/Share
|
|
Feb 14
2022
|
Lance Berberian EVP, CIO & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
799
-2.32%
|
$217,328
$272.68 P/Share
|
|
Feb 14
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-1.08%
|
$29,376
$272.68 P/Share
|
|
Feb 14
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
277
-0.62%
|
$75,344
$272.68 P/Share
|
|
Feb 14
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
778
-3.12%
|
$211,616
$272.68 P/Share
|
|
Feb 14
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
261
-6.52%
|
$70,992
$272.68 P/Share
|
|
Feb 12
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
284
+4.85%
|
-
|
|
Feb 12
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
284
+3.96%
|
-
|
|
Feb 12
2022
|
Lance Berberian EVP, CIO & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,708
+7.08%
|
-
|
|
Feb 12
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
317
+3.08%
|
-
|
|
Feb 12
2022
|
Glenn A Eisenberg Chief Financial Officer, EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
940
+2.07%
|
-
|
|
Feb 12
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,638
+9.25%
|
-
|
|
Feb 12
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
867
+18.46%
|
-
|
|
Feb 07
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
218
-3.96%
|
$60,386
$277.38 P/Share
|
|
Feb 07
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
204
-3.0%
|
$56,508
$277.38 P/Share
|
|
Feb 04
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
53
-4.29%
|
$14,681
$277.48 P/Share
|
|
Feb 04
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150
+10.82%
|
-
|
|
Feb 04
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-1.47%
|
$22,714
$277.48 P/Share
|
|
Feb 04
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+5.1%
|
-
|
|
Feb 04
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-14.26%
|
$22,991
$277.48 P/Share
|
|
Feb 04
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
267
+31.45%
|
-
|
|
Feb 04
2022
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
85
-5.81%
|
$23,545
$277.48 P/Share
|
|
Feb 04
2022
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
280
+16.07%
|
-
|
|
Feb 04
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
152
-2.18%
|
$42,104
$277.48 P/Share
|
|
Feb 04
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
560
+7.45%
|
-
|
|
Feb 04
2022
|
Adam H Schechter President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-7.89%
|
$391,124
$277.48 P/Share
|
|
Feb 04
2022
|
Adam H Schechter President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,507
+16.39%
|
-
|